Journal of Histochemistry and Cytochemistry Priciples for Free Access to Science
  Search:   
    >> Advanced Search

Guidelines | Subscriptions | About | exPRESS - Current - Archive | Business Information | Contact
Originally published as JHC exPRESS on June 16, 2006.
doi:10.1369/jhc.5A6900.2006
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data for this article
Right arrow All Versions of this Article:
jhc.5A6900.2006v1
54/9/991    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Steinfeld, R.
Right arrow Articles by Gärtner, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steinfeld, R.
Right arrow Articles by Gärtner, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Histochemistry and Cytochemistry
Volume 54 (9): 991-996, 2006
Copyright ©The Histochemical Society, Inc.

Detection of Tripeptidyl Peptidase I Activity in Living Cells by Fluorogenic Substrates

Robert Steinfeld, Jens C. Fuhrmann and Jutta Gärtner

Department of Pediatrics and Pediatric Neurology, University of Göttingen, Göttingen, Germany (RS,JG), and Centre for Molecular Neurobiology, University of Hamburg, Hamburg, Germany(JCF)

Correspondence to: Dr. Robert Steinfeld, Pädiatrie II, Zentrum Kinderheilkunde und Jugendmedizin, Universitätsklinikum Göttingen, Robert-Koch-Str. 40, D-37075 Göttingen, Germany. E-mail: rsteinfeld{at}med.uni-goettingen.de


   Summary
Top
 Summary
Introduction
 Materials and Methods
 Results
 Discussion
 Literature Cited
 
Tripeptidyl peptidase I (TPP-I) is a lysosomal peptidase with unclear physiological function. TPP-I deficiency is associated with late-infantile neuronal ceroid lipofuscinosis (NCL), a fatal neurodegenerative disease of childhood that is characterized by loss of neurons and photoreceptor cells. We have developed two novel fluorogenic substrates, [Ala-Ala-Phe]2-rhodamine 110 and [Arg-Nle-Nle]2-rhodamine 110, that are cleaved by TPP-I in living cells. Fluorescence of liberated rhodamine 110 was detected by flow cytometry and was dependent on the level of TPP-I expression. Rhodamine-related fluorescence could be suppressed by preincubation with a specific inhibitor of TPP-I. When investigated by fluorescent confocal microscopy, rhodamine signals colocalized with lysosomal markers. Thus, cleavage of these rhodamide-derived substrates is a marker for mature enzymatically active TPP-I. In addition, TPP-I-induced cleavage of [Ala-Ala-Phe]2-rhodamine 110 could be visualized in primary neurons. We conclude that [Ala-Ala-Phe]2-rhodamine 110 and [Arg-Nle-Nle]2-rhodamine 110 are specific substrates for determining TPP-I activity and intracellular localization in living cells. Further, these substrates could be a valuable tool for studying the neuronal pathology underlying classical late-infantile NCL. This article contains online supplemental material at http://www.jhc.org. Please visit this article online to view these materials. (J Histochem Cytochem 54:991–996, 2006)

Key Words: neuronal ceroid lipofuscinosis • tripeptidyl peptidase I • neurodegeneration • living cell cytochemistry • protease


   Introduction
Top
 Summary
 Introduction
Materials and Methods
 Results
 Discussion
 Literature Cited
 
TRIPEPTIDYL PEPTIDASE I (TPP-I, EC 3.4.14.9) is encoded by the CLN2 gene, which is associated with a fatal genetic neurodegenerative disease of childhood, classical late-infantile neuronal ceroid lipofuscinosis (NCL) (Sleat et al. 1997Go). A corresponding mouse model has recently been developed (Sleat et al. 2004Go). The CLN2 protein is synthesized as a 66-kDa precursor protein that is processed to a mature 46-kDa peptidase (Lin et al. 2001Go). CLN2 mutations found in NCL patients disrupt either the synthesis or the posttranslational processing and lysosomal targeting of TPP-I (Steinfeld et al. 2004Go). TPP-I can either act as aminopeptidase, cleaving tripeptides from the N terminus of small proteins at pH 4.0 (Vines and Warburton 1998Go; Warburton and Bernardini 2000Go), or show endopeptidase activity at pH 3.0 (Ezaki et al. 2000Go). A structurally and genetically unrelated tripeptidyl peptidase II has a similar aminopeptidase activity at pH 7.5. Tripeptidyl peptidase II (TPP-II, EC 3.4.14.10) is a cytosolic enzyme involved in the postproteosomal degradation of oligopeptides that are trimmed for major histocompatibility complex class I–mediated antigen presentation (Kloetzel 2004Go; Reits et al. 2004Go).

TPP-I shows homology to the sedolisin family of carboxyl proteinases (Wlodawer et al. 2003Go) and is presently the only known eukaryotic member of this proteinase family. The enzyme is ubiquitously expressed in mammalian tissues. TPP-I-deficient cells contain autofluorescent storage material that is the characteristic feature in patient cells of all types of NCL. Further, loss of TPP-I activity results in a selective degeneration of neuronal cells and retinal photoreceptor cells in NCL patients that is macroscopically characterized as cortical and cerebellar atrophy (Hofmann and Peltonen 2001Go). Current research is focused on the pathogenetic mechanisms that lead to the specific neuronal death.

The activity of TPP-I in cell lysates can be measured with the peptide substrate Ala-Ala-Phe-7-(4-methyl)coumarylamide (Vines and Warburton 1998Go) or with fluorescein isothiocyanate-labeled hemoglobin (Sohar et al. 2000Go). Recently, several other fluorescent substrates have been developed that are specifically cleaved by TPP-I in cell homogenates (Oyama et al. 2005Go; Tian et al. 2006Go) or used for histochemical TPP-I detection (Dikov et al. 2004Go). To study TPP-I activity in living cells, we have designed two new fluorogenic substrates, [Ala-Ala-Phe]2-rhodamine 110 and [Arg-Nle-Nle]2-rhodamine 110. Rhodamine-110–based peptide substrates are commonly used for in vivo detection of serine and cysteine proteases in mammalian cells (Leytus et al. 1983Go; Klingel et al. 1994Go; Hug et al. 1999Go). Ala-Ala-Phe and Arg-Nle-Nle are tripeptides that are known to precede TPP-I cleavage sites within other substrates (Vines and Warburton 1998Go; Tian et al. 2006Go). Our experiments demonstrate that the substrates [Ala-Ala-Phe]2-rhodamine 110 and [Arg-Nle-Nle]2-rhodamine 110 are preferentially cleaved by TPP-I and that the resulting fluorescent rhodamine 110 colocalizes with lysosomes.


   Materials and Methods
Top
 Summary
 Introduction
 Materials and Methods
Results
 Discussion
 Literature Cited
 
Reagents
[Ala-Ala-Phe]2-rhodamine 110 and [Arg-Nle-Nle]2-rhodamine 110 were synthesized by Thermo Electron, Ulm, Germany according to published methods (Klingel et al. 1994Go). Aliquots of the [Ala-Ala-Phe]2-rhodamine 110 substrate were dissolved in DMSO (5 mM) and stored at –80C. The peptide inhibitors Ala-Ala-Phe-chloromethylketone and Pro-Phe-Arg-chloromethylketone and the substrate Ala-Ala-Phe-[7-amido-4-methylcoumarin] were purchased from Bachem, Weil am Rhein, Germany. Rat anti-lamp-1 antibody was obtained from BD Pharmingen (Erembodegem, Belgium); mouse anti-synaptophysin (svp38) antibody came from Sigma-Aldrich (Munich, Germany), and mouse anti-MAP-2 antibody was purchased from Chemicon (Hampshire, UK). Anti-secretogranin II antibody was a gift from W. Huttner (Kromer et al. 1998Go). Secondary goat anti-rabbit, anti-rat, and anti-mouse antibodies conjugated to Alexa Fluor 546 or 633 were purchased from Molecular Probes (Leiden, The Netherlands). Rhodamine 110, protease inhibitors PMSF, pepstatin A, E64, leupeptin, bestatin, and apstatin, and all other reagents were purchased from Sigma-Aldrich.

Cells
Primary lymphocytes derived from NCL patients carrying the two most common pathogenic mutations, R208x and g.3556G>C in the CLN2 gene, and control lymphocytes derived from healthy individuals were immortalized by Epstein-Barr virus (EBV) transformation.

K562 cells (American Type Culture Collection; Manassas, VA) were transfected with a pcDNA3-TPP-I construct as described previously (Steinfeld et al. 2004Go). Stably TPP-I-expressing clones were selected in G418-containing medium. Single clones were achieved by the limited dilution procedure and extended for further analysis. Mouse fibroblasts and primary hippocampal neurons from newborn mice were prepared as described previously (Fuhrmann et al. 2002Go; Kasper et al. 2005Go).

TPP-I activity in cellular homogenates was assayed using the substrate Ala-Ala-Phe-[7-amido-4-methylcoumarin] as described previously (Vines and Warburton 1998Go). TPP-I-overexpressing K562 cells revealed a 16-fold higher TPP1 activity than wild-type K562 cells (data not shown).

For cytofluorometric enzyme assays, EBV-transformed lymphocytes and wild-type, TPP-I, or mock-transfected K562 cells were grown in DMEM/10% fetal calf serum (FCS) at 37C and 5% CO2 before analysis. EBV-transformed lymphocytes were washed twice in Hepes-buffered saline (HBS/2 mM EDTA) and then incubated with 5 µM of either [Ala-Ala-Phe]2-rhodamine or [Arg-Nle-Nle]2-rhodamine for 10 min at 37C. Washed wild-type or transfected K562 cells were preincubated with either Ala-Ala-Phe-chloromethylketone or Pro-Phe-Arg-chloromethylketone at concentrations of 0.2, 1, 5, and 25 µM for 10 min at 37C before the substrate [Ala-Ala-Phe]2-rhodamine (5 µM) was added and incubated for 10 min at 37C. After a short incubation period at 37C, the cells were cooled, the incubation volume was increased 10-fold by the addition of cold PBS, and the cells were kept at 8C for up to 8 hr before analysis in a FACSORT flow cytometer (Becton Dickinson; Mountain View, CA). Excitation was done at 488 nm and emission scanned between 500 nm and an emission peak at 529 nm (Leytus et al. 1983Go). Data were further analyzed and graphically displayed with the program Cell Quest (Becton Dickinson; Franklin Lakes, NJ). Additional control experiments were performed with 5 min preincubation of the following protease inhibitors: PMSF (0.5 mM), pepstatin A (150 µM), E 64 (10 µM), leupeptin (2 µM), bestatin (200 µM), and apstatin (120 µM).

Fluorescent Confocal Microscopy
Mouse fibroblasts were cultured on glass coverslips in DMEM/10% FCS at 37C and 5% CO2. The substrate was added at a concentration of 5 µM, and cells were incubated for 60 min at 37C. Fixation and staining were carried out at 4C to minimize diffusion of the rhodamine dye. After washing with PBS, cells were fixed with 4% (w/v) paraformaldehyde in PBS for 15 min. Antibody incubation was performed for 30 min for primary and 30 min for secondary antibodies, both in PBS with 3% (w/v) bovine serum albumin and 0.1% (w/v) saponin. After three washes with PBS, coverslips were mounted with Fluoromount G (Science Services; Munich, Germany) and analyzed with a Leica NTSC laser confocal microscope (Leica; Bensheim, Germany). Rhodamine 110 was excited using the 488 nm laser line, and emission was analyzed from 500–530 nm. Primary mouse neurons were grown on coverslips coated with polyornithine. At day 9, neurons were incubated with 15 µM [Ala-Ala-Phe]2-rhodamine for 60 min at 37C. Cells were fixed, stained, and mounted for fluorescence confocal microscopy as indicated above.


   Results
Top
 Summary
 Introduction
 Materials and Methods
 Results
Discussion
 Literature Cited
 
Using cytofluorometry, we measured the enzymatic conversion from the non-fluorescent bis-amide substrates [Ala-Ala-Phe]2-rhodamine 110 and [Arg-Nle-Nle]2-rhodamine 110 into the fluorescent free rhodamine 110. Immortalized lymphocytes derived from late-infantile NCL patients carrying pathogenic CLN2 mutations showed considerably less fluorescent signal intensity when compared with immortalized lymphocytes from control individuals (Figure 1 ). Incubation of control and TPP1–/– lymphoblasts with the cell supernatant containing free rhodamine 110 resulted in only minor diffusion of rhodamine 110 into cells (Supplemental Figure 1). K562 cells overexpressing TPP-I showed an increase in fluorescent signal intensity when compared with wild-type K562 cells. Preincubation of wild-type and TPP-I-overexpressing K562 cells with the specific inhibitor Ala-Ala-Phe-chloromethylketone caused a dose-dependent decrease in fluorescent signal intensity (Figures 2A and 2B). Extension of the incubation period at low temperature resulted in a considerable increase in the fluorescent signal intensities (Figures 2C and 2D). Preincubation with a non-inhibitory tripeptide-chloromethylketone compound (Pro-Phe-Arg-chloromethylketone) had only a minor effect on the fluorescent signal intensity (Figures 2E and 2F). Preincubation with the protease inhibitors PMSF, pepstatin A, E64, leupeptin, bestatin, and apstatin did not significantly change the resulting fluorescent signal intensity (data not shown). These results underline that the substrate [Ala-Ala-Phe]2-rhodamine is preferentially cleaved by intracellular TPP-I.


Figure 1
View larger version (14K):
[in this window]
[in a new window]
  		Figure 1

Detection of intracellular substrate cleavage in tripeptidyl peptidase I (TPP1)–/– and control lymphocytes. (A) Immortalized TPP1–/– lymphocytes (solid line) and control lymphocytes (dotted line) were incubated either without (0) or with 5 µM (5) of substrate [Ala-Ala-Phe]2-rhodamine for 4 hr at 8C before flow cytometry analysis. (B) Immortalized TPP1–/– lymphocytes (solid line) and control lymphocytes (dotted line) were incubated either without (0) or with 5 µM (5) of substrate [Arg-Nle-Nle]2-rhodamine for 4 hr at 8C before flow cytometry analysis. In both instances, control lymphocytes induced ~10-fold higher fluorescent signal intensities than did TPP1–/– lymphocytes.

 

Figure 2
View larger version (30K):
[in this window]
[in a new window]
  		Figure 2

Cytofluorometric measurement of intracellular TPP-I activity. Wild-type (wt) and CLN2-transfected (CLN2) K562 cells were preincubated with the inhibitor Ala-Ala-Phe-chloromethylketone or the non-inhibitor Pro-Phe-Arg-chloromethylketone at concentrations of 0, 0.2, 1, 5, and 25 µM before addition of 5 µM substrate ([Ala-Ala-Phe]2-rhodamine). Analyses were done after 20 min (A,B) and after 8 hr (C–F) incubation at 8C and the fluorescent signal intensity compared with untreated cells (no). (A) Wild-type K562 cells showed a dose-dependent suppression of the fluorescent signal by the inhibitor. (B) CLN2 K562 cells revealed higher fluorescent signal intensity for any concentration of added inhibitor. (C) Wild-type K562 cells showed a dose-dependent suppression by the inhibitor to 1.5-fold signal intensity of the background (no). (D) CLN2 K562 cells had on average 5-fold higher fluorescent signal intensity than wild-type K562 cells. (E) Wild-type K562 and (F) CLN2 K562 cells showed only a minimal suppression of fluorescent signal intensity by the non-inhibitor.

 
To further confirm our findings, we investigated by confocal microscopy the intracellular localization of the cleavage of the rhodamine substrates. Mouse fibroblasts were incubated with the substrate [Ala-Ala-Phe]2-rhodamine or the substrate [Arg-Nle-Nle]2-rhodamine before they were immunostained with markers specific for subcellular organelles. Rhodamine-dependent fluorescent signals colocalized with the lysosomal marker lamp-1 (Figure 3 ) and thus are associated with the localization of enzymatically active TPP-I (Steinfeld et al. 2004Go). In addition, we demonstrated subcellular localization of cleaved [Ala-Ala-Phe]2-rhodamine in primary mouse hippocampal neurons by fluorescence microscopy (Figure 4 ). Intracellular fluorescent signals were distributed in a punctate pattern covering neuronal cell bodies as well as proximal dendrites. Rhodamine 110 signals colocalized with the late endosomal/lysosomal marker lamp-1, but not with synaptophysin or secretogranin II, markers of synaptic and dense-core vesicles, respectively.


Figure 3
View larger version (118K):
[in this window]
[in a new window]
  		Figure 3

Localization of TPP-I activity by fluorescent confocal microscopy. Mouse fibroblasts were incubated with the substrate [Ala-Ala-Phe]2-rhodamine or [Arg-Nle-Nle]2-rhodamine for 1 hr at 37C, then cells were fixed and immunostained for the lysosomal marker lamp-1. (A) Only DMSO (0.1%) was added. (B) Substrate [Ala-Ala-Phe]2-rhodamine (5 µM). (C) Substrate [Arg-Nle-Nle]2-rhodamine (5 µM) was added. Free rhodamine 110–related fluorescent signal (green) showed a granular pattern and colocalized with lamp-1 immunoreactivity (red). Bar = 10 µm.

 

Figure 4
View larger version (106K):
[in this window]
[in a new window]
  		Figure 4

Localization of TPP-I activity in mouse hippocampal neurons. Primary mouse neurons were incubated with substrate [Ala-Ala-Phe]2-rhodamine for 1 hr at 37C, immunostained, and analyzed by fluorescent confocal microscopy. (A) Only DMSO (0.3%) was added, and cells were immunostained with lamp-1 (red). (B) Substrate [Ala-Ala-Phe]2-rhodamine (15 µM, green) was added, and cells were immunostained with lamp-1 (red). (C) Substrate [Ala-Ala-Phe]2-rhodamine (15 µM, green) was added, and cells were immunostained with synaptophysin (red). (D) Substrate [Ala-Ala-Phe]2-rhodamine (15 µM, green) was added, and cells were immunostained with secretogranin II and MAP-2 antibodies (red/blue). Free rhodamine 110–related staining (green) was detected in the neuronal soma, as well as in the proximal dendrites, and colocalized with the lysosomal marker lamp-1. Bar = 10 µm.

 

   Discussion
Top
 Summary
 Introduction
 Materials and Methods
 Results
 Discussion
Literature Cited
 
In our studies, we established a method to investigate the intracellular activity of TPP-I in living cells by fluorescent cytometry and fluorescent microscopy. We present experimental data indicating that TPP-I specifically cleaves the substrates [Ala-Ala-Phe]2-rhodamine and [Arg-Nle-Nle]2-rhodamine. TPP-I-deficient lymphocytes reveal significantly lower fluorescent signal intensity than control lymphocytes. Cells overexpressing TPP-I not only showed a greater signal of free fluorescent rhodamine 110 but also had consistently higher residual enzymatic activity when preincubated with increasing concentrations of the specific inhibitor Ala-Ala-Phe-chloromethylketone. In contrast, preincubation with comparable concentrations of the structurally similar compound Pro-Phe-Arg-chloromethylketone only slightly reduced the released fluorescent signal. Studies with TPP-I purified from rat spleen demonstrated the specific inhibition by Ala-Ala-Phe-chloromethylketone (Vines and Warburton 1998Go). Further, several known protease inhibitors and, in particular, aminopeptidase inhibitors had no significant effect on the detectable fluorescent signal. Importantly, this included PMSF, a potent serine protease inhibitor that is known to inhibit dipeptidyl peptidase II as well as TPP-II but not TPP-I (Wilson et al. 1993Go; Vines and Warburton 1998Go; Lin et al. 2001Go). Additional evidence that TPP-II is not involved in the intracellular cleavage of [Ala-Ala-Phe]2-rhodamine or [Arg-Nle-Nle]2-rhodamine is derived from the preferential lysosomal rather than cytosolic localization of the fluorescence signal when analyzed by confocal microscopy. It should be stressed that rhodamine 110 can penetrate membranes more easily than the non-cleaved bis-amide compounds. Therefore, the intracellular measured fluorescent signals are dependent on the cleavage of rhodamine substrates as well as on the diffusion of released rhodamine 110 into the extracellular space. To minimize the loss of released rhodamine 110, prolonged incubations should be performed at low temperature. However, we cannot exclude that the internalized substrates [Ala-Ala-Phe]2-rhodamine and [Arg-Nle-Nle]2-rhodamine are preferentially targeted to or better retained in lysosomes, and hence, tripeptidyl peptidase activities within non-lysosomal compartments are overall less-efficiently detected than are lysosomal compartments.

In summary, we have developed novel fluorogenic substrates for the analysis of intracellular TPP-I activity that are helpful in the study of the enzymatic activity of TPP-I in living cells and also its intracellular localization. These novel substrates are not only applicable to patients' lymphocytes and cultured fibroblasts but also to primary neurons. Thus, they will be an important future tool in the further elucidation of the specific pathomechanisms of neuronal degeneration associated with TPP-I deficiency and a key feature in understanding the disease pathogenesis of late-infantile NCL.


   Acknowledgments
 
We thank Prof. Dr. Schneppenheim and Mrs. Grabowski, Department of Pediatric Oncology, University Hospital Eppendorf, Hamburg for their support and their technical assistance in the usage of the FACSORT flow cytometer. We are grateful to Thomas Jentsch, in whose lab part of this work was done, and to W. Huttner for the secretogranin II antibody.


   Footnotes
 
Received for publication December 11, 2005; accepted May 31, 2006


   Literature Cited
Top
 Summary
 Introduction
 Materials and Methods
 Results
 Discussion
 Literature Cited
 

Dikov A, Dimitrova M, Krieg R, Halbhuber KJ (2004) New fluorescent method for the histochemical detection of tripeptidyl peptidase I using glycyl-l-prolyl-l-met-2-anthraquinonyl hydrazide as substrate. Cell Mol Biol 50:565–568. Published online December 31, 2004 (DOI:10.1170/70)

Ezaki J, Takeda-Ezaki M, Oda K, Kominami E (2000) Characterization of endopeptidase activity of tripeptidyl peptidase-I/CLN2 protein which is deficient in classical late infantile neuronal ceroid lipofuscinosis. Biochem Biophys Res Commun 268:904–908[CrossRef][Medline]

Fuhrmann JC, Kins S, Rostaing P, El Far O, Kirsch J, Sheng M, Triller A, et al. (2002) Gephyrin interacts with Dynein light chains 1 and 2, components of motor protein complexes. J Neurosci 22:5393–5402[Abstract/Free Full Text]

Hofmann SL, Peltonen L (2001) The neuronal ceroid lipofuscinoses. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, McGraw-Hill, 3877–3894

Hug H, Los M, Hirt W, Debatin KM (1999) Rhodamine 110-linked amino acids and peptides as substrates to measure caspase activity upon apoptosis induction in intact cells. Biochemistry 38:13906–13911[CrossRef][Medline]

Kasper D, Planells-Cases R, Fuhrmann JC, Scheel O, Zeitz O, Ruether K, Schmitt A, et al. (2005) Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration. EMBO J 24:1079–1091[CrossRef][Medline]

Klingel S, Rothe G, Kellermann W, Valet G (1994) Flow cytometric determination of cysteine and serine proteinase activities in living cells with rhodamine 110 substrates. Methods Cell Biol 41:449–459[Medline]

Kloetzel PM (2004) Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII. Nat Immunol 5:661–669[CrossRef][Medline]

Kromer A, Glombik MM, Huttner WB, Gerdes HH (1998) Essential role of the disulfide-bonded loop of chromogranin B for sorting to secretory granules is revealed by expression of a deletion mutant in the absence of endogenous granin synthesis. J Cell Biol 140:1331–1346[Abstract/Free Full Text]

Leytus SP, Melhado LL, Mangel WF (1983) Rhodamine-based compounds as fluorogenic substrates for serine proteinases. Biochem J 209:299–307[Medline]

Lin L, Sohar I, Lackland H, Lobel P (2001) The human CLN2 protein/tripeptidyl-peptidase I is a serine protease that autoactivates at acidic pH. J Biol Chem 276:2249–2255[Abstract/Free Full Text]

Oyama H, Fujisawa T, Suzuki T, Dunn BM, Wlodawer A, Oda K (2005) Catalytic residues and substrate specificity of recombinant human tripeptidyl peptidase I (CLN2). J Biochem (Tokyo) 138:127–134[Abstract/Free Full Text]

Reits E, Neijssen J, Herberts C, Benckhuijsen W, Janssen L, Drijfhout JW, Neefjes J (2004) A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity 20:495–506[CrossRef][Medline]

Sleat DE, Donnelly RJ, Lackland H, Liu CG, Sohar I, Pullarkat RK, Lobel P (1997) Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science 277:1802–1805[Abstract/Free Full Text]

Sleat DE, Wiseman JA, El-Banna M, Kim KH, Mao Q, Price S, Macauley SL, et al. (2004) A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration. J Neurosci 24:9117–9126[Abstract/Free Full Text]

Sohar I, Lin L, Lobel P (2000) Enzyme-based diagnosis of classical late infantile neuronal ceroid lipofuscinosis: comparison of tripeptidyl peptidase I and pepstatin-insensitive protease assays. Clin Chem 46:1005–1008[Free Full Text]

Steinfeld R, Steinke HB, Isbrandt D, Kohlschutter A, Gartner J (2004) Mutations in classical late infantile neuronal ceroid lipofuscinosis disrupt transport of tripeptidyl-peptidase I to lysosomes. Hum Mol Genet 13:2483–2491[Abstract/Free Full Text]

Tian Y, Sohar I, Taylor JW, Lobel P (2006) Determination of the substrate specificity of tripeptidyl-peptidase I using combinatorial peptide libraries and development of improved fluorogenic substrates. J Biol Chem 281:6559–6572[Abstract/Free Full Text]

Vines D, Warburton MJ (1998) Purification and characterisation of a tripeptidyl aminopeptidase I from rat spleen. Biochim Biophys Acta 1384:233–242[CrossRef][Medline]

Warburton MJ, Bernardini F (2000) Tripeptidyl-peptidase I deficiency in classical late-infantile neuronal ceroid lipofuscinosis brain tissue. Evidence for defective peptidase rather than proteinase activity. J Inherit Metab Dis 23:145–154[CrossRef][Medline]

Wilson C, Gibson AM, McDermott JR (1993) Purification and characterization of tripeptidylpeptidase-II from post-mortem human brain. Neurochem Res 18:743–749[CrossRef][Medline]

Wlodawer A, Durell SR, Li M, Oyama H, Oda K, Dunn BM (2003) A model of tripeptidyl-peptidase I (CLN2), a ubiquitous and highly conserved member of the sedolisin family of serine-carboxyl peptidases. BMC Struct Biol 3:8[CrossRef][Medline]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data for this article
Right arrow All Versions of this Article:
jhc.5A6900.2006v1
54/9/991    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Steinfeld, R.
Right arrow Articles by Gärtner, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steinfeld, R.
Right arrow Articles by Gärtner, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


Guidelines | Subscriptions | About | exPRESS - Current - Archive | Business Information | Contact